Frequency of nodular goiter and autoimmune thyroid disease and association of these disorders with insulin resistance in polycystic ovary syndrome

Author(s):  
Mellia Karakose ◽  
Sema Hepsen ◽  
Erman Cakal ◽  
Muyesser Arslan ◽  
Esra Tutal ◽  
...  
Endocrine ◽  
2014 ◽  
Vol 49 (2) ◽  
pp. 464-469 ◽  
Author(s):  
Cevdet Duran ◽  
Mustafa Basaran ◽  
Orkide Kutlu ◽  
Zehra Kucukaydin ◽  
Suleyman Bakdik ◽  
...  

2015 ◽  
Vol 10 (2) ◽  
pp. 47-52
Author(s):  
Aslı DOĞRUK ÜNAL ◽  
Özlem TARÇIN ◽  
Özlem CİĞERLİ ◽  
Hülya PARILDAR ◽  
Betül UĞUR ALTUN ◽  
...  

Author(s):  
Chun-Wei Ho ◽  
Hsin-Hung Chen ◽  
Ming-Chia Hsieh ◽  
Ching-Chu Chen ◽  
Sheng-Pang Hsu ◽  
...  

Objective: To investigate the prevalence of polycystic ovary syndrome (PCOS) and its comorbidities in patients with autoimmune thyroid disease (AITD). Population: In this cohort study, patients newly diagnosed as having Hashimoto thyroiditis (HT) or Grave disease (GD) were recruited into the AITD group. Method: The logistic regression model was used to investigate the association between exposure, endpoint, later diseases and treatment. Main Outcome Measures: We assessed the cumulative incidence using the Kaplan–Meier method and verified the difference by the log-rank test. Results: The AITD group included 3599 GD patients and 1332 HT patients. PCOS risk in patients with AITD was higher than that in the control group (adjusted hazard ratio = 1.39; 95% confidence interval = 1.07–1.71). In patients with both AITD and PCOS, the odds ratios of diabetes, hyperlipidemia and coronary artery disease were 2.48, 2.05 and 2.63, respectively. Conclusions: The risks of PCOS and its comorbidities such as diabetes, dyslipidemia and cardiac artery disease are high in patients with AITD in Taiwan.


Endocrine ◽  
2015 ◽  
Vol 53 (2) ◽  
pp. 538-542 ◽  
Author(s):  
Giovanna Muscogiuri ◽  
Stefano Palomba ◽  
Mario Caggiano ◽  
Domenico Tafuri ◽  
Annamaria Colao ◽  
...  

Author(s):  
Reveka Gyftaki ◽  
Sofia Gougoura ◽  
Nikolaos Kalogeris ◽  
Vasiliki Loi ◽  
George Koukoulis ◽  
...  

2020 ◽  
Author(s):  
Zeineb Jenouiz ◽  
Hajer Kandara ◽  
Nedra Bendag ◽  
Radhouan Gharbi ◽  
Manel Jemel ◽  
...  

2019 ◽  
Vol 17 (5) ◽  
pp. 455-464 ◽  
Author(s):  
Alfonso Mate ◽  
Antonio J. Blanca ◽  
Rocío Salsoso ◽  
Fernando Toledo ◽  
Pablo Stiefel ◽  
...  

Pregnancy hypertensive disorders such as Preeclampsia (PE) are strongly correlated with insulin resistance, a condition in which the metabolic handling of D-glucose is deficient. In addition, the impact of preeclampsia is enhanced by other insulin-resistant disorders, including polycystic ovary syndrome and obesity. For this reason, there is a clear association between maternal insulin resistance, polycystic ovary syndrome, obesity and the development of PE. However, whether PE is a consequence or the cause of these disorders is still unclear. Insulin therapy is usually recommended to pregnant women with diabetes mellitus when dietary and lifestyle measures have failed. The advantage of insulin therapy for Gestational Diabetes Mellitus (GDM) patients with hypertension is still controversial; surprisingly, there are no studies in which insulin therapy has been used in patients with hypertension in pregnancy without or with an established GDM. This review is focused on the use of insulin therapy in hypertensive disorders in the pregnancy and its effect on offspring and mother later in life. PubMed and relevant medical databases have been screened for literature covering research in the field especially in the last 5-10 years.


Sign in / Sign up

Export Citation Format

Share Document